Vimseltinib manufacturers & suppliers

Vimseltinib

Form: Capsules

Strength: 14 mg; 20 mg; 30 mg

Reference Brands: Romvimza

Category: Oncology Cancer Care

Vimseltinib, an investigational oncology drug, is regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality according to GMP standards. In the US, regulatory review involves validation, safety assessments, and clinical trial data submission. In the EU, approval processes include validation, stability testing, and conformity with MDR standards. These dossiers encompass safety profiles, clinical trial results, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to innovative therapies that support cancer treatment, advancing patient care and clinical outcomes globally.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Atezolizumab

Strength: 1200 mg/20 mL

Form: Intravenous infusion

Reference Brands: Tecentriq® (EU & US)

View Details
Durvalumab

Strength: 120 mg/4 mL, 500 mg/10 mL

Form: Injection

Reference Brands: Imfinzi® (US & EU)

View Details
Sunitinib

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg

Form: Tablet

Reference Brands: Sutent® (EU & US)

View Details
Ifosfamide

Strength: 1 g/vial,2 g/vial, 3 g/vial

Form: Injection

Reference Brands: Ifex® (US), Holoxan® (EU)

View Details

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.